Thanks.
It is worth noting the below as this is quite important for likelihood of success of dosing and readouts for the AML trials. Simplistically the historic data is like a crystal ball for the results to come.
In AML, Bisantrene achieved complete responses rates 40% to 72% range (average 52%) as a single-agent in 5 out 5 historic Phase II trials (1987 to 1994) .
Even with effectively half the number of cycles ( no consolidation course given ), the Israel trial that finished in 2020 achieved a 40% response rate ( effectively with half the drug given ). This was the reduction in tumour size in that 2020 trial.
![]()
The above result mid 2020 plus the release of the Cancer Cell paper about 10 days later drove a 269% rerate in the share price over a 1 month period.
![]()
- Forums
- ASX - By Stock
- RAC
- RAC - Charts & Price Action
RAC - Charts & Price Action, page-5949
-
- There are more pages in this discussion • 16,149 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.68 |
Change
-0.030(1.75%) |
Mkt cap ! $286.2M |
Open | High | Low | Value | Volume |
$1.73 | $1.73 | $1.68 | $119.9K | 70.42K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3012 | $1.66 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 6382 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3012 | 1.660 |
1 | 1205 | 1.650 |
1 | 3067 | 1.630 |
1 | 615 | 1.620 |
2 | 18200 | 1.615 |
Price($) | Vol. | No. |
---|---|---|
1.700 | 6382 | 1 |
1.735 | 609 | 1 |
1.750 | 10096 | 2 |
1.780 | 4483 | 1 |
1.790 | 1000 | 1 |
Last trade - 15.07pm 03/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |